356 related articles for article (PubMed ID: 21876460)
41. A novel pro-inflammatory mechanism of action of resistin in human endothelial cells: up-regulation of SOCS3 expression through STAT3 activation.
Pirvulescu M; Manduteanu I; Gan AM; Stan D; Simion V; Butoi E; Calin M; Simionescu M
Biochem Biophys Res Commun; 2012 Jun; 422(2):321-6. PubMed ID: 22575502
[TBL] [Abstract][Full Text] [Related]
42. SOCS3 suppresses AP-1 transcriptional activity in neuroblastoma cells through inhibition of c-Jun N-terminal kinase.
Miao T; Wu D; Zhang Y; Bo X; Xiao F; Zhang X; Magoulas C; Subang MC; Wang P; Richardson PM
Mol Cell Neurosci; 2008 Feb; 37(2):367-75. PubMed ID: 18055217
[TBL] [Abstract][Full Text] [Related]
43. [Correlation of Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) to fascin and phosphorylated Stat3 in nasopharyngeal carcinoma].
Liu QY; Han AJ; You SY; Dong Y; Yang QX; Wu JH; Li MF
Ai Zheng; 2008 Oct; 27(10):1070-6. PubMed ID: 18851787
[TBL] [Abstract][Full Text] [Related]
44. Chronic tumor necrosis factor-alpha treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes.
Ishizuka K; Usui I; Kanatani Y; Bukhari A; He J; Fujisaka S; Yamazaki Y; Suzuki H; Hiratani K; Ishiki M; Iwata M; Urakaze M; Haruta T; Kobayashi M
Endocrinology; 2007 Jun; 148(6):2994-3003. PubMed ID: 17379643
[TBL] [Abstract][Full Text] [Related]
45. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
46. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes.
Prêle CM; Keith-Magee AL; Yerkovich ST; Murcha M; Hart PH
Immunology; 2006 Sep; 119(1):8-17. PubMed ID: 16925527
[TBL] [Abstract][Full Text] [Related]
47. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E; Monnien F; Kim S; Ivanaj A; N'Guyen T; Demarchi M; Adotevi O; Thierry-Vuillemin A; Jary M; Kantelip B; Pivot X; Godet Y; Degano SV; Borg C
Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
[TBL] [Abstract][Full Text] [Related]
48. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
Gao Y; Cimica V; Reich NC
J Biol Chem; 2012 Jun; 287(25):20904-12. PubMed ID: 22547065
[TBL] [Abstract][Full Text] [Related]
49. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
50. EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma.
Caudron A; Battistella M; Feugeas JP; Pages C; Basset-Seguin N; Mazouz Dorval S; Funck Brentano E; Sadoux A; Podgorniak MP; Menashi S; Janin A; Lebbé C; Mourah S
Exp Dermatol; 2016 Aug; 25(8):618-22. PubMed ID: 27060463
[TBL] [Abstract][Full Text] [Related]
51. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma.
Ying M; Li D; Yang L; Wang M; Wang N; Chen Y; He M; Wang Y
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1617-26. PubMed ID: 20155426
[TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
53. SOCS3 promotor hypermethylation and STAT3-NF-κB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells.
Dhar K; Rakesh K; Pankajakshan D; Agrawal DK
Am J Physiol Heart Circ Physiol; 2013 Mar; 304(6):H776-85. PubMed ID: 23335796
[TBL] [Abstract][Full Text] [Related]
54. Expression of suppressor of cytokine signalling 3 (SOCS3) in human bladder epithelial cells infected with uropathogenic Escherichia coli.
Demirel I; Säve S; Kruse R; Persson K
APMIS; 2013 Feb; 121(2):158-67. PubMed ID: 23030674
[TBL] [Abstract][Full Text] [Related]
55. A preliminary immunohistochemical study of signal transducer and activator of transcription (STAT) proteins in primary oral malignant melanoma.
Nikitakis NG; Gkouveris I; Papadopoulou E; Daskalopoulos A; Sklavounou A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Feb; 125(2):164-171. PubMed ID: 29249519
[TBL] [Abstract][Full Text] [Related]
56. Protective role of JAK/STAT signaling against renal fibrosis in mice with unilateral ureteral obstruction.
Koike K; Ueda S; Yamagishi S; Yasukawa H; Kaida Y; Yokoro M; Fukami K; Yoshimura A; Okuda S
Clin Immunol; 2014 Jan; 150(1):78-87. PubMed ID: 24333535
[TBL] [Abstract][Full Text] [Related]
57. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.
Kim HS; Park YH; Lee J; Ahn JS; Kim J; Shim YM; Kim JH; Park K; Han J; Ahn MJ
Cancer; 2010 Feb; 116(3):676-85. PubMed ID: 20052735
[TBL] [Abstract][Full Text] [Related]
58. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis.
Huang FJ; Steeg PS; Price JE; Chiu WT; Chou PC; Xie K; Sawaya R; Huang S
Cancer Res; 2008 Dec; 68(23):9634-42. PubMed ID: 19047140
[TBL] [Abstract][Full Text] [Related]
59. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction.
Hiwatashi K; Tamiya T; Hasegawa E; Fukaya T; Hashimoto M; Kakoi K; Kashiwagi I; Kimura A; Inoue N; Morita R; Yasukawa H; Yoshimura A
Cancer Lett; 2011 Sep; 308(2):172-80. PubMed ID: 21624767
[TBL] [Abstract][Full Text] [Related]
60. Effects of Reducing Suppressors of Cytokine Signaling-3 (SOCS3) Expression on Dendritic Outgrowth and Demyelination after Spinal Cord Injury.
Park KW; Lin CY; Li K; Lee YS
PLoS One; 2015; 10(9):e0138301. PubMed ID: 26384335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
